WO2005034841A3 - Anthrax vaccine - Google Patents

Anthrax vaccine Download PDF

Info

Publication number
WO2005034841A3
WO2005034841A3 PCT/US2004/014971 US2004014971W WO2005034841A3 WO 2005034841 A3 WO2005034841 A3 WO 2005034841A3 US 2004014971 W US2004014971 W US 2004014971W WO 2005034841 A3 WO2005034841 A3 WO 2005034841A3
Authority
WO
WIPO (PCT)
Prior art keywords
anthrax vaccine
anthracis
yeast
proteins
optimized
Prior art date
Application number
PCT/US2004/014971
Other languages
French (fr)
Other versions
WO2005034841A2 (en
Inventor
Robert Hepler
Kathrin Jansen
Rosemarie Kelly
Myra Kurtz
Maria C Losada
Loren Schultz
Original Assignee
Merck & Co Inc
Robert Hepler
Kathrin Jansen
Rosemarie Kelly
Myra Kurtz
Maria C Losada
Loren Schultz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Robert Hepler, Kathrin Jansen, Rosemarie Kelly, Myra Kurtz, Maria C Losada, Loren Schultz filed Critical Merck & Co Inc
Publication of WO2005034841A2 publication Critical patent/WO2005034841A2/en
Publication of WO2005034841A3 publication Critical patent/WO2005034841A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention provides DNA sequences that encode Bacillus anthracis Protective Antigen (PA) proteins that can be used for prophylactic immunization against anthrax infections. The codon usage in the sequence is optimized for expression in the yeast, including strains of Saccharomyces cerevisiae, a known safe fermentation source for vaccine products. The invention also includes vaccines and methods of vaccination against B. anthracis.
PCT/US2004/014971 2003-05-14 2004-05-13 Anthrax vaccine WO2005034841A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47056303P 2003-05-14 2003-05-14
US60/470,563 2003-05-14

Publications (2)

Publication Number Publication Date
WO2005034841A2 WO2005034841A2 (en) 2005-04-21
WO2005034841A3 true WO2005034841A3 (en) 2005-09-15

Family

ID=34434803

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/014971 WO2005034841A2 (en) 2003-05-14 2004-05-13 Anthrax vaccine

Country Status (1)

Country Link
WO (1) WO2005034841A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
CN101495644B (en) 2006-05-30 2012-11-07 陶氏环球技术有限责任公司 Codon optimization method
US20110110968A1 (en) * 2009-11-12 2011-05-12 Stanley Goldman Human optimized Bacillus anthracis protective antigen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002522A2 (en) * 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Anthrax vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002522A2 (en) * 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Anthrax vaccine

Also Published As

Publication number Publication date
WO2005034841A2 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
WO2007024941A3 (en) Polyvalent vaccine
NO20061876L (en) Optimized expression of HPV45-L1 in ferns
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
TW200519203A (en) Optimized expression of HPV 58 L1 in yeast
WO2004058157A3 (en) Yeast-based vaccines as immunotherapy
WO2003024481A3 (en) Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
WO2006031264A3 (en) Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
FR15C0079I1 (en)
WO2010019262A3 (en) Polyvalent vaccine
WO2006020071A3 (en) Vaccines against aids comprising cmv/r-nucleic acid constructs
IL164812A0 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
PT1487485E (en) Imidazoquinoline adjuvants for dna vaccines
WO2007056266A3 (en) Cd40 ligand fusion protein vaccine
WO2002034205A3 (en) Using heat shock proteins to increase immune response
EP1220925B8 (en) Chlamydia antigens and corresponding dna fragments and uses thereof
WO2007081896A3 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
WO2002032943A3 (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
WO2003066094A3 (en) Hepatitis b vaccines
WO2003059385A3 (en) Hiv vaccine and method of use
WO2008060385A3 (en) Li-key enhanced vaccine potency
WO2002024739A3 (en) Spas-1 cancer antigen
WO2002034773A3 (en) Streptococcal genes
WO2005058349A3 (en) Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases
WO2004032860A3 (en) Hiv vaccine formulations
WO2009074861A3 (en) Improved vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase